News

1. The 21st IMDRF Management Committee Meeting (Virtual)

The 21st International Medical Device Regulators Forum (IMDRF) Management Committee (MC) meeting was held virtually on April 21. It was chaired by the Therapeutic Goods Administration, Australia, and Dr. KUSAKABE Tetsuya (International Coordination Officer) and two staff members from the Office of International Programs of the PMDA along with a staff member from the Ministry of Health, Labour and Welfare (MHLW) attended.

A closed meeting was held for regulatory members and official observers to discuss guidance documents drafts and future work items. At the meeting, two draft guidance documents from the Cybersecurity Working Group: the Marketing Review Report Work Instruction from the Good Regulatory Review Practice Working Group for public consultation and the Practices for the Cybersecurity of Legacy Medical Devices were approved; Machine Learning-enabled Medical Devices: Key Terms and Definitions from the AI Medical Device Working Group was approved as the final document; IMDRF Standards Liaison Program Framework from the Standards Working Group was approved for publication; the Software as a Medical Device Working Group was established to revise related guidance documents for new work item; the timeline of the ongoing work item, Expanding the Harmonization of Adverse Event Terminology, was extended; and they also agreed to a change of Working Group chair from Adverse Event Terminology Working Group.

In addition to the discussion of guidance documents etc., the MC agreed to the Medicines and Healthcare Products Regulatory Agency (MHRA) in UK becoming an IMDRF MC member.

The next IMDRF MC meeting is scheduled for September 2022 in Australia (hybrid).

The detailed outcome of the IMDRF MC Meeting will be available on the following website:
http://www.imdrf.org/meetings/meetings.asp

2. ICH meeting in Athens

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on the 21 - 25 May, in Athens, Greece. The ICH meetings have been held virtually for two years because of the COVID-19 pandemic, but this was the first meeting that was held in a hybrid format, combining in-person and virtual formats. Dr. NAKASHIMA Nobumasa (Associate Executive Director for International Programs, PMDA), Working Group experts, and Mr. YASUDA Naoyuki (Office Director, Office of International Regulatory Affairs from the Ministry of Health, Labour and Welfare (MHLW), attended these meetings with other officers from the MHLW and PMDA.

The main outcome of the meeting included further expansion of the ICH membership. The ICH Assembly welcomed the Medicines and Healthcare products Regulatory Agency (MHRA) UK as a new member, and the National Agency of Pharmaceutical Products (ANPP), Algeria as a new observer, bringing ICH membership to a total of 20 Members and 35 Observers.

At this meeting, M10 reached Step 4 for Guidelines on “Bioanalytical Method Validation and Study Sample Analysis”; M7(R2) reached Step 4 for Q&As on "Assessment and Control of DNA Reactive Mutagenic Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk”; M8 reached Step 4 for Q&As on “eCTD v4.0 Specification Change Request Document v1.7 and eCTD v4.0 Implementation Package v1.5”; and M12 reached Step 2 for the new M12 guidelines on “Drug Interaction Studies.”

The “Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials” was adopted as a new topic and initiating the development of a new ICH Efficacy Guideline was agreed on.

The next ICH meeting is scheduled for November 12 to 16, 2022, in Incheon, Korea.
3. ASEAN-Japan Risk Management Plan Symposium 2022

The ASEAN-Japan Risk Management Plan Symposium 2022 was held virtually on May 23, and was co-hosted by the Indonesian Food and Drug Authority (Indonesian FDA), the PMDA and the University of Indonesia.

The symposium was supported by the Japan-ASEAN Integration Fund (JAIF) to deepen the knowledge of the Risk Management Plan (RMP) for regulators in ASEAN Member States (AMS). The target of the symposium was the regulator industry, and academia from AMS and 283 people participated in the symposium.

The symposium began with an inaugural address by Ms. Mayagustina Andarini, Deputy Chairperson of the Indonesian FDA. Representatives from the Office of Pharmacovigilance I/II, PMDA, the Indonesian FDA, and the Japan Pharmaceutical Manufacturers Association (JPMA) then delivered lectures on the Risk Management Plan (RMP). Each lecture was followed by a live question-and-answer session to promote understanding of the RMP.

At the end of the symposium, Mr. UZU Shinobu, Senior Executive Director of the PMDA, delivered the closing address. The next symposium will be held in Indonesia in 2023.

The details of the symposium are available at the following link: https://aseanrmp.ui.ac.id

4. ASEAN-Japan Risk Management Plan Seminar 2022

The ASEAN-Japan Risk Management Plan Seminar 2022 was held virtually on May 24 and 25, and was co-hosted by the Indonesian FDA, PMDA, and the University of Indonesia.

The target of the seminar was the regulators of ASEAN Member States (AMS). Seventy-two participants, including 44 observers, attended the seminar. Like the symposium, this seminar was also supported by the JAIF.

At the seminar, the PMDA staff from the Office of Pharmacovigilance I/II and representatives of the JPMA delivered lectures on the Risk Management Plan (RMP) and labeling. Group work on RMP development was also conducted. The participants actively exchanged opinions and deepened their understanding.

The next seminar will be held in Indonesia in 2023.

The details of the seminar are available at the following link: https://aseanrmp.ui.ac.id
5. China-Japan Medical and Health Forum

The China-Japan Medical and Health Forum was held on May 25, 2022. It was hosted by the Chinese Peasants’ and Workers’ Democratic Party, and more than 100 people from the PMDA, Medical Excellence Japan (MEJ), National Medical Products Administration (NMPA), and members of the academia and industry attended the event. In the forum, topics such as the implementation status of China's Pharmaceutical Administration Law, the regulation and evaluation of pharmaceuticals and medical devices in China, and consideration for the Chinese marketing authorization holder system were presented by representatives of the regulatory authorities, including the NMPA, the Center for Drug Evaluation (CDE), and the Center for Medical Device Evaluation (CMDE). Representatives from the PMDA presented on regulatory initiatives during the COVID-19 pandemic, the review of cellular and tissue-based products, and the promotion of pediatric drug development in Japan. Innovations in Japanese clinical trials were presented by the National Cancer Center (NCC). Industry presentations were also made and a range of information was exchanged between regulatory authorities, the academia, and industry representatives from Japan and China.

6. Call for Applications: PMDA-ATC & U.S. FDA Pediatric Review Webinar 2022

The PMDA Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC), together with the Food and Drug Administration of the United States (U.S. FDA), will hold the “PMDA-ATC & U.S. FDA Pediatric Review Webinar 2022,” on September 5 (preliminary session) and from September 12 to 15. This seminar was designed for pediatric drug application reviewers from overseas regulatory authorities. The objective of the seminar was to provide participants with the opportunity to learn about global standard guidelines on the review of drug products being developed for the pediatric population, to acquire knowledge and perspectives on a wide range of topics including pediatric clinical trials, through lectures and case studies, and apply them towards the development of pediatric drugs in the participants’ own countries or regions.

Please refer to the following website for details of the PMDA-ATC & U.S. FDA Pediatric Review Seminar 2022.

https://www.pmda.go.jp/english/symposia/0236.html

7. PMDA-ATC E-learning Updated Content Information

The PMDA-ATC E-learning system has been operational since January 2020. This month, we are pleased to announce the release of two recent videos entitled, “Drug Master File (MF) System in Japan” and “Approval Review Quoting Drug Master File.”

These videos introduce the Japanese MF registration system, where the intellectual properties of API (Active Pharmaceutical Ingredient) manufacturers are protected while ensuring drug quality and the consideration points
in the MF registration system, as well as the effective approval review process referring MF and MF change management after the approval of the drug.

Please refer to the following link to access the e-learning website:

---

**English Translations of Review Reports**

The following links provide the latest information on the English versions of the review reports on the PMDA website.

**Pharmaceuticals**
https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Non-Proprietary Name</th>
<th>Posting Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actemra</td>
<td>tocilizumab (genetical recombination)</td>
<td>May 12, 2022</td>
</tr>
<tr>
<td>[Partial Change Approval]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opdivo</td>
<td>nivolumab (genetical recombination)</td>
<td>May 31, 2022</td>
</tr>
<tr>
<td>[Partial Change Approval]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forxiga</td>
<td>dapagliflozin propylene glycolate hydrate</td>
<td>June 3, 2022</td>
</tr>
<tr>
<td>[Partial Change Approval]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Twymeeg</td>
<td>imeglimin hydrochloride</td>
<td>June 8, 2022</td>
</tr>
<tr>
<td>[Initial Approval]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Regenerative Medical Products**
https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html
Safety Information

PMDA Medical Safety Information No.58 Revised version (May)
Introduction of Connectors to Prevent Misconnection (for Enteral Applications)

Pharmaceuticals and Medical Devices Safety Information No. 392 (June 10, 2022)
1. Revision of Precautions for Somatropin (genetical recombination)
2. Revisions of Precautions for Interferon Beta-1a (genetical recombination) and Interferon Beta-1b (genetical recombination)
3. New Project Development of the “Japan Drug Information Institute in Pregnancy”
4. Important Safety Information
   1. [1] Dexamethasone (oral dosage form) (preparations indicated for pituitary suppression tests) (and 9 others)
5. Revision of Precautions (No. 332)
   Coronavirus modified uridine RNA vaccine (SARS-CoV-2) (Comirnaty intramuscular injection) (and 15 others)
6. List of Products Subject to Early Post-marketing Phase Vigilance

Pharmaceuticals Revisions of PRECAUTIONS (June 10, 2022)
   • Coronavirus modified uridine RNA vaccine (SARS-CoV-2) (Comirnaty intramuscular injection)
   • Coronavirus modified uridine RNA vaccine (SARS-CoV-2) (Comirnaty intramuscular injection for 5 to 11 years old)
   • Coronavirus modified uridine RNA vaccine (SARS-CoV-2) (Spikevax Intrammmuscular Injection (former brand name: COVID-19 Vaccine Moderna Intramuscular Injection))

Pharmaceuticals Revisions of PRECAUTIONS (June 14, 2022)
   • Cetuximab sarotalocan sodium (genetical recombination)
   • Nivolumab (genetical recombination)
   • Pembrolozumab (genetical recombination)
   • Vonoprazan fumarate/amoxicillin hydrate/metronidazole
   • Rabeprazole sodium/amoxicillin hydrate/metronidazole
   • Nirmatrelvir/ritonavir
   • Molnupiravir
   • Metronidazole (oral dosage form)
   • Metronidazole (injections)

Events
Conferences/Meetings that the PMDA will participate in or host

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 12</td>
<td>ARISE-PMDA Joint symposium for Asian Clinical Trial</td>
<td>Virtual</td>
</tr>
</tbody>
</table>
Reports from Overseas
Our officers deliver lively reports of their activities at their stationed overseas authorities.

Post COVID-19 measurement
EMA has published “the list of critical medicines for the COVID-19 public health emergency” on 8th June 2022. This list included the authorized medicines/vaccines considered critical for the management and prevention of COVID-19. This list was adapted on 7th June 2022 at Medicines Shortages Steering Group (MSSG). The MSSG was established on March 2022 under Regulation (EU) 2022/123, which to ensure a robust response to the issues of medicines supply caused by the public health emergencies. The members of the MSSG include the representatives of EU member states, representative of the European Commission, and EMA representative.

The list published on 7th June 2022 is a post-measure to address potential shortages, supply and demand issues related to the medicines in the list, which will be closely monitored to avoid potential shortages. Marketing authorization holders for medicines on the list will regularly provide EMA with information on potential and existing shortages, including available stocks and forecasts of supply and demand. In addition, national competent authorities will provide regular reports on estimated demand for these medicines at national level. From this information, MSSG will assess the status of deficiencies that are critical to protect public health during an emergency situation, and recommend and coordinate appropriate EU-level actions to the European Commission and EU Member States.

The MSSG adapted this list following consultation with the Medicines Shortages Single Point of Contact Working Party (SPOC WP), the Emergency Task Force (ETF) and EMA’s Patients’ and Consumers’ Working Party (PCWP) and Healthcare Professionals’ working Party (HCPWP). Moreover, this list has been shared with EU industry trade associations.

Based on the various lessons learned from the COVID-19 pandemic, I believe that such in-depth measures against potential shortages in emergency situations will become very important in the future.


Ms. UEDA Mami
PMDA’s International Liaison Officer stationed at EMA in the Netherlands